A simple free-catch urine analysis system for non-invasive detection and monitoring of canine transitional cell carcinoma (TCC)/urothelial carcinoma (UC) – the most common form of canine bladder and prostate cancer. 
Content Author did not provide alt text
Content Author did not provide alt text

Leaders in Molecular Diagnostics

We are pioneers, innovators, and researchers – and we are also dog lovers. That’s why we are driven to understand the biological and environmental influences of canine cancer, to create solutions for accurate and early detection that will help to enhance the health and welfare of our canine companions. Our products feature forensic-level sensitivity and are supported by robust research, proven science and leading genetics and oncology experts.

Content Author did not provide alt text

Background on TCC and UC

This year in the US, approximately 80,000 dogs will be diagnosed with canine transitional cell carcinoma (TCC) of the urinary tract, also known as urothelial carcinoma (UC). The disease affects the bladder, urethra, and kidneys of male and female dogs and also the prostate of males. Symptoms include straining to urinate, repeated frequent attempts to urinate, blood in the urine, and repeated bacterial infection.

TCC/UC accounts for an estimated 1-2% of all cancer cases diagnosed in dogs, and can affect any breed; however the disease shows remarkably elevated incidence in several popular breeds. These, when combined, account for over a third of all diagnosed TCC/UC cases in purebred dogs.

High-risk breeds include the American Eskimo Dog, Australian Cattle Dog, Australian Shepherd, Beagle, Bichon Frise, Border Collie, Parson Russell Terrier, Lhasa Apso, Rat Terrier, Russell Terrier, Scottish Terrier, Shetland Sheepdog, West Highland White Terrier, and Wire Fox Terrier.

To learn more about the traditional path to diagnosis of canine TCC/UC, click here. 

Content Author did not provide alt text

Research offers a new DNA-based strategy for detection of TCC/UC from free-catch urine

Our research has shown that a single mutation in a gene called BRAF is present in 85% of confirmed cases of canine TCC/UC. Using state-of-the-art molecular technology, we have developed a DNA-based assay, CADET BRAF, that can detect the presence of this mutation in malignant cells shed naturally into the urine of a tumor-bearing dog.
Through rigorous validation in hundreds of clinical specimens, we have shown that the mutation is not found in the urine of healthy dogs, or from dogs that have benign bladder polyps, inflammation or chronic cystitis. In cases that subsequently have undergone biopsy of a visible mass, we have also shown full concordance between the presence of a BRAF mutation in free-catch urine and subsequent pathology-based confirmation of a TCC/UC. The presence of the mutation in canine urine is therefore a highly specific indicator of the presence of a TCC/UC.
To learn more about the science behind the development of CADET® BRAF, click on this link to read the published study.
Content Author did not provide alt text

How cadet BRAF is Used in a Clinical Setting

CADET BRAF evaluates urine samples from dogs for the presence of cells harboring the BRAF mutation. The assay identifies the 85% of TCC/UC cases that are associated with the BRAF mutation.
The forensic level of detection of the assay can detect as few as 10 mutation-bearing cells in a urine sample and so is able to detect the presence of a developing TCC/UC, often several months before any advanced clinical signs associated with the cancer become evident. This enables owners and veterinarians to initiate appropriate treatment very early in the course of the disease, potentially before the mass has become invasive.  Dogs already presenting with urinary symptoms that may be caused by a TCC/UC can be evaluated for the presence of a TCC/UC simply by submitting a urine sample to Antech Diagnostics.   
Additionally, the assay offers a sensitive means to monitor BRAF-mutant TCC/UC cases during the course of their treatment, for therapeutic response and relapse.  We have developed CADET BRAF exclusively for expedited assessment of dogs displaying symptoms consistent with TCC/UC, and for cases undergoing treatment.

To order a CADET BRAF test, please download a test request form here. 

Content Author did not provide alt text

What Are the Key Advantages of CADET BRAF?

Convenient: The free-catch urine system is non-invasive, allowing specimens to be collected while the patient is at the clinic, or by the owner at home.

Sensitive: The assay permits forensic-level detection for earliest detection of emerging TCC/UC.

Affordable: Timely detection of TCC/UC allows owners to direct their resources toward effective treatment of the cancer itself, rather than the non-specific symptoms.

Robust: Unlike similar tests, CADET BRAF is not affected by the presence of blood, protein, sugars, bacteria, etc. in the urine.

Rapid: Results are available in just 2-3 business days from receipt of the sample.


CADET BRAF-PLUS provides further evaluation of those dogs that present with clinical signs consistent with TCC/UC but for which no BRAF mutation is detected. CADET BRAF-PLUS increases the sensitivity for detection of canine bladder and prostate cancers to >95%.
If the specimen is eligible, Antech  will automatically run CADET BRAF-PLUS.
Content Author did not provide alt text
Content Author did not provide alt text

Frequently Asked Questions

How do I order a CADET BRAF test?
To order a CADET BRAF test, please download a test request form here. 

What supplies are required to run the CADET BRAF diagnostic?
To run the CADET BRAF test, Antech supplies customers with a urine specimen collection container that contains a small amount of preservative. The container can be returned to Antech in a standard specimen bag. Customers can request reasonable quantities of the specimen container.

What is the procedure for collecting and shipping urine samples to Antech Diagnostics? 
You can download instructions here.